Non-small cell lung cancer (NSCLC) has the largest number of identified therapeutic targets, some of which have therapeutic utility. The use of next-generation sequencing facilitates accurate molecular diagnosis and allows the detection of other emerging mutations, such as the HER2 mutation and biomarkers predictive of response to immunotherapy. In this consensus, a group of experts […]
Researchers at the University of Wisconsin School of Medicine and Public Health (Madison, WI, USA) have developed a blood test that is able to detect multiple types of cancer in a relatively simpler and less expensive way compared to other tests in development. The test detects specific signs of cancer in the blood using a
BLOOD TEST TO DETECT CANCER BY IDENTIFYING CIRCULATING TUMOR DNA Read More »
In this single-center retrospective analysis, the response of 76 patients with high-risk myelodysplastic syndrome (MDS) treated with azacitidine (AZA) was reviewed, especially the cytogenetic response (CGR) to determine the response to treatment and the possible impact of karyotype evolution (KE) on the course of the disease. So far, the only treatment option with curative potential
Patients with non-basal triple-negative breast cancer are those who benefit most from chemotherapy with oral capecitabine as adjuvant treatment, according to a new analysis of the patient population of the phase III clinical trial GEICAM/2003-11_CIBOMA/2004-01, called GEICAM/CIBOMA, carried out by GEICAM and the Ibero-American Coalition for Research in Breast Oncology (CIBOMA). The results of the study
Immunochemotherapy and the search for biomarkers mark a paradigm shift in lung cancer. The possibilities offered by these treatments in combination with conventional tools, such as chemotherapy, have doubled the five-year survival of patients, as well as the median overall survival in advanced stages. Specifically, the application of immunotherapy and chemotherapy is already a standard
In this double-blind phase III clinical trial, patients with newly diagnosed ovarian cancer and a BRCA mutation (germline or somatic) who responded to platinum-based chemotherapy were randomized to receive Olaparib or placebo for up to 2 years. After a 7-year follow-up, prespecified analysis of overall survival was reported. This is the longest follow-up of a
Sarcomas have undergone important advances in their diagnosis and treatment in recent years. For this reason, coinciding with Sarcoma Day in Spain, which is celebrated on September 20, SEOM has updated the advances in this pathology. Certain aspects of therapeutic management have been consolidated, as well as the use of certain drugs approved in recent
SEOM UPDATES ON DIAGNOSTIC AND THERAPEUTIC ADVANCES IN SARCOMAS Read More »
The incidence of brain metastases continues to increase, currently affecting 25% of cancer patients. But currently available therapies have limited efficacy and fail to improve survival limited efficacy and fail to improve survival. To address this situation, the team led by Manuel Valiente, head of the Brain Metastasis Group at the Spanish National Cancer Research
NEW DRUG SCREENING METHOD FOR THE TREATMENT OF BRAIN METASTASES Read More »
The U.S. Food and Drug Administration (FDA) has approved the drug capmatinib (Tabrecta) for adult patients with metastatic non-small cell lung cancer (NSCLC), whose tumors have a genetic mutation that results in the loss of exon 14 of the MET (mesenchymal-epithelial transition gene) gene. The approval was based on a trial of 160 patients with
TABRECTA GAINS FULL FDA APPROVAL FOR NON-SMALL CELL LUNG CANCER Read More »
